Helixa Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-12-2024
- Paid Up Capital ₹ 0.10 M
as on 15-12-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Revenue 57.33%
(FY 2020)
- Profit -75.18%
(FY 2020)
- Ebitda -29.84%
(FY 2020)
- Net Worth 19.05%
(FY 2020)
- Total Assets -13.35%
(FY 2020)
About Helixa Lifesciences
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Viplav Lakshmisathyanarayana, Sravani Doddala, Doddala Mahadev, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999TG2017PTC120315
- Company No.
120315
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Oct 2017
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Helixa Lifesciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Viplav Lakshmisathyanarayana  | Director | 30-Oct-2017 | Current |
| Sravani Doddala | Director | 07-Apr-2020 | Current |
| Doddala Mahadev | Director | 30-Oct-2017 | Current |
| Venu Sudheer | Director | 19-Feb-2018 | Current |
Financial Performance of Helixa Lifesciences.
Helixa Lifesciences Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 57.33% increase. The company also saw a substantial fall in profitability, with a 75.18% decrease in profit. The company's net worth Soared by an impressive increase of 19.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Helixa Lifesciences?
In 2018, Helixa Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Fastronix Private LimitedActive 4 years 1 monthViplav Lakshmisathyanarayana and Venu Sudheer are mutual person
- Xyz Innovations Private LimitedActive 6 years 11 months
Viplav Lakshmisathyanarayana is a mutual person
- Thinkgreen Impex Private LimitedActive 7 years 8 months
Viplav Lakshmisathyanarayana and Sravani Doddala are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Helixa Lifesciences?
Unlock and access historical data on people associated with Helixa Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Helixa Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Helixa Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
